17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: This phase I trial is studying the side effects and best dose of
17-N-allylamino-17-demethoxygeldanamycin in treating patients with solid tumors that cannot
be removed by surgery.